Last Day
Biotechnology
Latest Valuation
- Trailing PE:
- Forward PE:
- Price Sales TTM:
- Price Book MRQ:
- Enterprise Value:
- Enterprise Value Revenue:
- Enterprise Value Ebitda:
- Beta:
Key Highlights
- Shares Outstanding:
- Market Capitalization:
- Market Capitalization Mln:
- EBITDA:
- PE Ratio:
- PEG Ratio:
- Wall Street Target Price:
- Book Value:
- Dividend Share:
- Dividend Yield:
- Earnings Share:
- EPS Estimate Current Year:
- EPS Estimate Next Year:
- EPS Estimate Next Quarter:
- EPS Estimate Current Quarter:
- Most Recent Quarter:
- Profit Margin:
- Operating Margin TTM:
- Return On Assets TTM:
- Return On Equity TTM:
- Revenue TTM:
- Revenue Per Share TTM:
- Quarterly Revenue Growth YOY:
- Gross Profit TTM:
- Diluted Eps TTM:
- Quarterly Earnings Growth YOY:
Basic Information
- Type:
- Name:
- Exchange:
- Currency Code:
- Currency Name:
- Currency Symbol:
- Country Name:
- Fiscal Year End:
- IPO Date:
- International Domestic:
- Sector:
- Industry:
- Address:
- Country:
- Listings:
- Web URL:
- Full Time Employees:
- Updated At:
- Gic Sector:
- Gic Group:
- Gic Industry:
- Gic SubIndustry:
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Address: 195 Church Street, New Haven, CT, United States, 06510